Case Control Study
Copyright ©The Author(s) 2017.
World J Gastrointest Pharmacol Ther. Nov 6, 2017; 8(4): 193-200
Published online Nov 6, 2017. doi: 10.4292/wjgpt.v8.i4.193
Table 1 Patient demographic and clinical characteristic according to response to anti-TNF treatment
CharacteristicsRespondersPartial respondersPrimarily non-responders
n (%)72 (67.29)22 (21.57)13 (14.74)
Age (yr, mean ± SD)34.10±11.6332.23 ± 13.3139.09 ± 15.60
Sex (%)
Male30 (41.67)14 (63.64)10 (76.92)
Female42 (62.69)8 (36.36)3 (23.08)
C-reactive protein (mg/dL, mean ± SD)
Baseline3.10 ± 2.034.13 ± 2.316.86 ± 2.89
After treatment0.88 ± 1.842.21 ± 2.693.96 ± 2.81
δC-reactive protein (%)80.44 ± 22.4271.94 ± 45.7458.04 ± 22.63
Duration of disease (yr)6.38 ± 5.915.71 ± 3.774.00 ± 3.13
Infliximab dose (mg/kg)555
Location
L224 (33.34)3 (13.64)2 (15.38)
L345 (62.50)19 (86.36)11 (84.62)
L43 (4.48)00
Behavior
B131 (43.06)7 (31.82)5 (38.46)
B213 (18.06)6 (27.27)2 (15.38)
B328 (38.89)9 (40.91)6 (46.15)